EN DE

Chia Tai Enterprises International Ltd (3839) Fair Value & Analysis

Healthcare · HK · Market cap HK$2.1B

CT Chia Tai Enterprises International Ltd 3839 · HK
PriceHK$8.78
Fair ValueHK$2.58
Upside-70.6%
Quality68/100
Watch Chia Tai Enterprises International Ltd for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 6.4% net margin
Low debt · generates free cash flow
Ranks above peers (9/14)
Narrow moat 42/100
Evidence: Medium Range HK$1.62 – HK$3.23 Share as image

Fair value as of: Aug 13, 2026

From 26 valuation models · updated 3 days ago

Share price −3.0% over the past month.

A solid business, but screening 71% overvalued on our models.

Fair value for all 35,000+ stocks, review alerts and the diversification check: 14 days of Pro free, no card.

What matters now

  • The price sits above even our optimistic bull case (HK$3.23). The favourable scenario is already priced in.
  • Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder.
  • A fairly wide model range (HK$1.62 to HK$3.23) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

HK$9.85 HK$0.6500 Fair Value HK$2.58 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$0.6500 – HK$9.85 · fair‑value band HK$1.62 – HK$3.23 · the HK$8.78 price screens above the HK$2.58 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Chia Tai Enterprises International Ltd (3839) currently trades at HK$8.78, while our model-based Fair Value estimate is HK$2.58, implying the stock looks roughly 70.6% overvalued today. The Quality Score stands at 68/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Chia Tai Enterprises International Ltd generated revenue of HK$470M at a net margin of 6.4%. Revenue declined 40.0% year over year. It earns a return on equity of 11.5%. Net debt stands at HK$7.7M. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$1.62 (bear case) to HK$3.23 (bull case); at HK$8.78, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 13% below its 52-week high and 94% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -71%, 3839 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF HK$1.82 HK$3.26 HK$5.97 80
Residual Income HK$1.04 HK$1.19 HK$2.22 76
Rev-Margin DCF HK$1.75 HK$3.38 HK$5.87 74
All 26 models by family
DCF Models
FCF DCF HK$1.91 HK$2.98 HK$6.10 38
Owner Earnings HK$2.30 HK$4.95 HK$10.29 31
5Y Revenue Exit HK$1.75 HK$3.11 HK$5.80 39
5Y EBITDA Exit HK$2.02 HK$3.68 HK$6.76 41
5Y P/E Exit HK$2.12 HK$4.37 HK$7.32 38
10Y Revenue Exit HK$1.73 HK$3.50 HK$5.34 36
10Y EBITDA Exit HK$1.98 HK$4.01 HK$7.80 37
10Y P/E Exit HK$2.05 HK$4.20 HK$7.99 35
Earnings-Based
Graham-Dodd HK$0.9100 HK$6.32 HK$8.88 54
Lynch FV HK$1.99 HK$2.84 HK$3.70 50
PEG = 1.0 HK$1.99 HK$2.84 HK$3.70 46
EPV HK$1.32 HK$1.51 HK$1.67 59
Dividend Discount
Gordon GGM HK$0.3600 HK$0.7300 HK$1.10 70
DDM Multi-Stage HK$0.3600 HK$0.6300 HK$0.7700 61
Multiples
P/E Multiple HK$2.10 HK$2.80 HK$3.50 63
P/S Multiple HK$1.70 HK$2.27 HK$2.83 58
P/B Multiple HK$1.70 HK$2.27 HK$2.83 55
EV/EBIT HK$2.19 HK$2.88 HK$3.57 53
EV/EBITDA HK$2.09 HK$2.74 HK$3.39 54
EV/Revenue HK$1.60 HK$2.23 HK$2.86 43
Asset-Based
NCAV (Graham) HK$0.5800 HK$0.7700 HK$1.15 50
Growth DCF
Growth DCF HK$1.82 HK$3.26 HK$5.97 80
Rev-Margin DCF HK$1.75 HK$3.38 HK$5.87 74
Economic Profit
Residual Income HK$1.04 HK$1.19 HK$2.22 76
ROIC Compounder HK$1.47 HK$2.02 HK$2.47 72
Growth Earnings
Growth-Adj P/E HK$2.67 HK$3.82 HK$4.96 68

Widest divergence: Growth Earnings (HK$3.82) versus Dividend Discount (HK$0.6300). Highest evidence: Growth DCF (80).

Notify me when 3839 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) HK$470M
Revenue growth (YoY) -40.0%
Net margin 6.4%
Return on equity 11.5%
Free cash flow HK$28.0M FY2025
P/E ratio 8.9 as of Jul 2, 2026
More key figures
Operating margin 7.3%
EPS (TTM) HK$0.6759
EPS growth (YoY) +23.3%
Net debt HK$7.7M FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 68/100

Of which business quality 67 · Market factors (momentum, volatility) 53

Profitability 50
Margins and returns on capital today
Quality Growth 82
Are margins and returns improving?
Cashflow 46
Earnings quality: real cash, not paper profit
Fin. Strength 82
Balance sheet, leverage, solvency risk
Investment 74
Disciplined investing over empire-building
Low Volatility 3
Calm price path (market factor)
Momentum 72
Price trend over the last 3–12 months (market factor)
52W Momentum 79
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Chia Tai Enterprises International Limited manufactures and sells animal health products and chlortetracycline in Mainland China, the Asia Pacific, the Americas, Europe, and internationally. It operates through two segments: Biotech Business and Investment Business.

Full company description

Chia Tai Enterprises International Limited manufactures and sells animal health products and chlortetracycline in Mainland China, the Asia Pacific, the Americas, Europe, and internationally. It operates through two segments: Biotech Business and Investment Business. The Biochemical segment is engaged in the manufacture and/or sale of animal health products and chlortetracycline, which are used as feed additives to promote growth of livestock, prevent or cure animal diseases, and enhance efficiency under the Shihao and Citifac brand names. The Investment segment is engaged in the trading of machinery and the manufacture and sale of automotive parts; and caterpillar products, including excavators, power generators, bulldozers and compactors, as well as spare parts; and the manufacture and sale of motorcycle carburetors. The company serves livestock farms, pharmaceutical companies, trading companies, feed mills, automobile manufacturers, and motorcycle manufacturers. The company was formerly known as Ek Chor China Motorcycle Co. Ltd. Chia Tai Enterprises International Limited was incorporated in 1987 and is based in Central, Hong Kong.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Chia Tai Enterprises International Ltd reported revenue of HK$537M in FY2025 versus HK$142M in FY2021, a compound +39.3%/yr. Reported net income was HK$32.1M in FY2025, compounding +13.2%/yr from FY2021.

Growth Quality 85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
HK$537M
Latest YoY
+74.4%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+49.9%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+41.8%
Avg. growth/yr (13Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+11.4%
Revenue +39.3%/yr
FY21 HK$142M
FY22 HK$159M
FY23 HK$174M
FY24 HK$308M
FY25 HK$537M
Net income +13.2%/yr
FY21 HK$19.6M
FY22 −HK$6.7M
FY23 HK$2.6M
FY24 HK$11.2M
FY25 HK$32.1M
Character of growth · EPS growth decomposed (2014-2025) +6.2 % p.a.
Revenue per share +15.8 pp

of which total revenue +16.1 pp · buybacks/dilution −0.3 pp

EBIT margin −11.7 pp
Tax rate +0.6 pp
Residual (interest, one-offs) +1.5 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

3839 screens 71% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Chia Tai Enterprises International Ltd · Fair Value
HK$2.58 −71%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Chia Tai Enterprises International Ltd Fair Value". https://www.fairvalue-calculator.com/stock/3839

Peer Group

Drug Manufacturers - Specialty & Generic · 622 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 68 · Top 25%
Fair Value upside −71% · Bottom 25%
Return on equity (TTM) 12% · Above median
Return on assets 5% · Above median
Net margin (TTM) 6% · Above median
Operating margin (TTM) 7% · Below median
Revenue growth -40% · Bottom 25%
Dividend yield (TTM) 0.5% · Bottom 25%
Debt / equity 0.03× · Lower than median

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 8.9× · Cheaper than 75% of peers
P/B 0.97× · Cheaper than median
P/S (TTM) 0.57× · Cheaper than 75% of peers
P/FCF 9.6× · Pricier than 75% of peers
EV/EBITDA 5.2× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 7
FUTURE 0 · sector 21
PAST 46 · sector 25
HEALTH 98 · sector 97
DIVIDEND 9 · sector 32

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥53.76 ¥25.94 -52%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,944 ₹989.50 -49%
Divi's Laboratories Limited DIVISLAB ₹8,500 ₹1,932 -77%
Torrent Pharmaceuticals Limited TORNTPHARM ₹4,915 ₹1,163 -76%
PharmaEssentia Corporation 6446 1,440 TWD 233.93 TWD -84%
Cipla Limited CIPLA ₹1,463 ₹1,001 -32%
Zydus Lifesciences Limited ZYDUSLIFE ₹1,167 ₹703.32 -40%
Lupin Limited LUPIN ₹2,281 ₹2,477 +9%
Mankind Pharma Limited MANKIND ₹2,433 ₹983.11 -60%
Dr. Reddy's Laboratories Limited DRREDDY ₹1,200 ₹874.79 -27%

Compare Chia Tai Enterprises International Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Chia Tai Enterprises International Ltd (3839) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of HK$2.58 versus a price of HK$8.78, about −71% (overvalued).
What is the fair value of 3839?
Our model-based fair value for Chia Tai Enterprises International Ltd is HK$2.58 (as of Aug 13, 2026), built from audited fundamentals. The current price is HK$8.78.
What is the quality score of 3839?
Chia Tai Enterprises International Ltd has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Chia Tai Enterprises International Ltd (3839)?
Chia Tai Enterprises International Ltd reported trailing-twelve-month revenue of about HK$470M (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 3839?
The net profit margin of Chia Tai Enterprises International Ltd is about 6.4%, meaning it keeps roughly 6.4% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Chia Tai Enterprises International Ltd and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.